Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS) - Tabular View

This Tabular View shows the required WHO registration data elements as marked by ^†

Tracking Information

First Received Date ^†

June 9, 2008

Last Updated Date

June 10, 2008

Start Date ^†

March 2007

Current Primary Outcome Measures ^†

Improvement on the Motor Activity Log [ Time Frame: One year ] [ Designated as safety issue: No ]

Original Primary Outcome Measures ^†

Same as current

Change History

Complete list of historical versions of study NCT00695084 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^†

Improvement on the Wolf Motor Function Test [ Time Frame: Pre to post-treatment ] [ Designated as safety issue: No ]

Original Secondary Outcome Measures ^†

Same as current

Descriptive Information

Brief Title ^†

Constraint-Induced (CI) Movement Therapy for Progressive Multiple Sclerosis (MS)

Official Title ^†

Constraint-Induced Movement Therapy Trial for Progressive Multiple Sclerosis

Brief Summary

This trial will evaluate whether progressive multiple sclerosis associated with hemiparesis may benefit from Constraint-Induced Movement Therapy.

Detailed Description

Constraint-Induced Movement Therapy was developed to treat stroke hemiparesis. Due to the similarity between multiple sclerosis and stroke in terms of chronic motor deficit, this trial will attempt to determine whether multiple sclerosis may benefit similarly from Constraint-Induced Movement Therapy.

Study Phase

Phase I

Study Type ^†

Interventional

Study Design ^†

Treatment, Open Label, Single Group Assignment, Efficacy Study

Condition ^†

Multiple Sclerosis

Intervention ^†

Behavioral: Constraint-Induced Movement Therapy

Study Arms / Comparison Groups

Experimental: Treatment with Constraint-Induced Movement Therapy

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^†

Completed

Enrollment ^†

Completion Date

April 2008

Primary Completion Date

April 2008 (final data collection date for primary outcome measure)

Eligibility Criteria ^†

Inclusion Criteria:

Chronic upper extremity motor deficit due to multiple sclerosis

Exclusion Criteria:

Relapse within 3 months of planned enrollment.

Gender

Both

Ages

21 Years to 80 Years

Accepts Healthy Volunteers

Contacts ^††

Location Countries ^†

United States

Expanded Access Status

Administrative Information

NCT ID ^†

NCT00695084

Responsible Party

Patricia O'Looney, National Multiple Sclerosis Society

Secondary IDs ^††

PP1395

Study Sponsor ^†

National Multiple Sclerosis Society

Collaborators ^††

Investigators ^†

Principal Investigator:

Victor W Mark, MD

University of Alabama at Birmingham

Information Provided By

National Multiple Sclerosis Society

Verification Date

June 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.